Indivior PLC (LON: INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder...
The latest addition comes in the area of cannabis-related disorders, as Indivior buys an option to license a CB1 inhibitor from France’s Aelis Farma for the treatment of diseases like cannabis addiction and cannabis-induced psychosis. They’re putting down $30 million in cash and promising a $100 million license fee payment should they decide to exercise the option after seeing Phase IIb data.